{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-087893","form_type":"8-K","ticker":"DERM","cik":"0001867066","company_name":"Journey Medical Corp","filed_at":"2022-08-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:57.542908+00:00","generated_at":"2026-06-24T02:21:59.337349+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Journey Medical Q2 net revenue up 20% to $18.3M; loss narrows to $7.5M","bullets":["Net revenue $18.3M (+20% YoY), driven by new product launches despite Targadox generic competition.","Net loss $7.5M ($0.43/sh) vs. $11.9M ($1.30/sh) in Q2 2021; Adjusted EBITDA loss $2.6M.","DFD-29 Phase 3 rosacea trials 45% enrolled; top-line data expected H1 2023, NDA in H2 2023.","Settlement with Padagis solidifies exclusivity for QBREXZA, AMZEEQ, ZILXI; supply chain delays resolved.","Tenth dermatology product launch planned in H2 2022; salesforce expanded from 42 to 84 reps."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-087893","json":"https://secwatch.observer/filing/0001104659-22-087893.json","markdown":"https://secwatch.observer/filing/0001104659-22-087893.md","text":"https://secwatch.observer/filing/0001104659-22-087893.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1867066/000110465922087893/0001104659-22-087893-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1867066/000110465922087893/tm2222960d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T02:21:59.337349+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}